Joy Gibson, MD, PhD

Dr. Gibson’s laboratory seeks to optimize treatment regimens for challenging infections. Our primary focus is management of drug-resistant bacterial infections in cystic fibrosis, particularly non-tuberculous mycobacteria. We utilize a hollow fiber infection model to optimize current therapeutics and test novel treatment approaches in vitro.

• Albert Einstein College of Medicine, Bronx, NY — MD, PhD — 05/2013
• University of Colorado School of Medicine, Aurora, CO — 06/2016 — Pediatrics Residency
• Children's Hospital Los Angeles, Los Angeles, CA — 07/2023 — Pediatric Infectious Diseases Fellowship

• Antibiotic optimization
• Drug-resistant bacteria
• Cystic Fibrosis
• Pharmacokinetics-pharmacodynamics

• Treatment of Allergic Bronchopulmonary Aspergillosis with Dupilumab Reduces IgE Levels and is Well Tolerated in Three Children with Cystic Fibrosis. Pediatr Allergy Immunol Pulmonol. 2026 Sep 11; 2151321.. View in PubMed
• Polymicrobial interactions influence Mycobacterium abscessus co-existence and biofilm forming capabilities. Front Microbiol. 2024; 15:1484510.. View in PubMed
• Transcriptome profiles of macrophages upon infection by morphotypic smooth and rough variants of Mycobacterium abscessus. Microbes Infect. 2024 Jul-Aug; 26(5-6):105367.. View in PubMed
• Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergence. Microbiol Spectr. 2024 02 06; 12(2):e0322223.. View in PubMed
• Growth medium and nitric oxide alter Mycobacterium abscessus morphotype and virulence. Microbiol Res. 2021 Dec; 253:126887.. View in PubMed

• Neely, Michael
• Beringer, Paul
• Smith, Beth
• Klausner, Jeffrey
• Burgener, Elizabeth
• Hsiao, Jennifer